Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

spinal cord cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Nuclear Factor of activated T Cells (NFAT) (1) Akt (2) Aminopeptidase (1) Apoptosis (8) Autophagy (2) Bcl-2 Family (1) Cathepsin (1) COX (1) Cytochrome P450 (1) Ferroptosis (1) Formyl Peptide Receptor (FPR) (2) Gap Junction Protein (2) Lactate Dehydrogenase (1) LPL Receptor (1) MEK (1) mGluR (1) mTOR (2) NF-κB (1) NO Synthase (1) NOD-like Receptor (NLR) (1) p38 MAPK (1) Parasite (2) PARP (1) PERK (3) Phosphatase (1) PI3K (2) Potassium Channel (1) Prostaglandin Receptor (1) Proteasome (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) SOD (1) Sodium Channel (1) Tau Protein (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (1) Inflammation/Immunology (7) Metabolic Disease (4) Neurological Disease (13)

By Targets:

Nuclear Factor of activated T Cells (NFAT) (1)

Akt (2)

Aminopeptidase (1)

Apoptosis (8)

Autophagy (2)

Bcl-2 Family (1)

Cathepsin (1)

COX (1)

Cytochrome P450 (1)

Ferroptosis (1)

Formyl Peptide Receptor (FPR) (2)

Gap Junction Protein (2)

Lactate Dehydrogenase (1)

LPL Receptor (1)

MEK (1)

mGluR (1)

mTOR (2)

NF-κB (1)

NO Synthase (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (1)

Parasite (2)

PARP (1)

PERK (3)

Phosphatase (1)

PI3K (2)

Potassium Channel (1)

Prostaglandin Receptor (1)

Proteasome (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (2)

SOD (1)

Sodium Channel (1)

Tau Protein (1)

By Research Areas:

Cancer (8)

Cardiovascular Disease (1)

Endocrinology (1)

Inflammation/Immunology (7)

Metabolic Disease (4)

Neurological Disease (13)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor Programmed Cell Death 4 (PDCD4)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-118355

ALLM Calpain inhibitor II	Proteasome Cathepsin	Neurological Disease
ALLM (Calpain inhibitor II) is a potent inhibitor of calpain and cathepsin proteases. ALLM inhibits neuronal cell death and improves chronic neurological function after spinal cord injury (SCI) .

HY-P2275

Peptide5	Gap Junction Protein	Neurological Disease
Peptide5, a connexin 43 mimetic peptide, reduce animals swelling, astrogliosis, and neuronal cell death after spinal cord injury

HY-P5982

PTPσ Inhibitor, ISP	Phosphatase	Neurological Disease
PTPσ Inhibitor, ISP can bind to recombinant human PTPs and inhibits PTPσ signaling. PTPσ Inhibitor, ISP can penetrate the membrane and relieves the chondroitin sulfate proteoglycan (CSPG)-mediated axonal sprouting inhibition in spinal cord injury model. PTPσ Inhibitor, ISP enhances remyelination in LPC-induced demyelinated spinal cord. PTPσ Inhibitor, ISP also promotes oligodendrocyte progenitor cells (OPCs) migration, maturation, remyelination, and functional recovery in animal models of Multiple Sclerosis (MS) .

HY-P2275B

Peptide5 TFA	Gap Junction Protein NOD-like Receptor (NLR)	Inflammation/Immunology
Peptide5 TFA, a connexin 43 mimetic peptide, reduces animals swelling, astrogliosis, and neuronal cell death after spinal cord injury. Peptide5 TFA also inhibits NLRP3 inflammasome, and is an anti-inflammatory agent .

HY-114810

Prostaglandin F2α serinol amide	Prostaglandin Receptor	Endocrinology
Prostaglandin F2α serinol amide is a serinolamide G protein-coupled receptor that increases calcium levels in human non-small cell lung cancer cells. Prostaglandin F2α is also a luteinizing hormone in sheep and may be a nociceptive mediator in the spinal cord .

HY-130553

β-Spaglumic acid 1 Publications Verification β-NAAG; β-N-Acetylaspartylglutamic acid	Aminopeptidase mGluR	Neurological Disease
β-Spaglumic acid (β-NAAG) is a competitive NAAG peptidase inhibitor (K_i=1 µM) that protects spinal cord neurons from excitotoxicity and hypoxic damage. β-Spaglumic acid is also a selective mGluR3 antagonist (mGluR3 receptor functions to regulate activity-dependent synaptic potentiation in the hippocampus). β-Spaglumic acid can be used in neuroprotection-related studies .

HY-145313

TTBK1-IN-2	Tau Protein	Neurological Disease
TTBK1-IN-2 (compound 29) is a potent Tau-Tubulin kinase (TTBK1) inhibitor with IC₅₀s of 0.24 and 4.22 µM, respectively. TTBK1-IN-2 reveals good brain penetration in vivo and is able to reduce TDP-43 phosphorylation not only in cell cultures but also in the spinal cord of transgenic TDP-43 mice .

HY-N0911

Rehmannioside A 1 Publications Verification	NF-κB Apoptosis p38 MAPK Ferroptosis Cytochrome P450 Reactive Oxygen Species (ROS) SOD Lactate Dehydrogenase PERK MEK Bcl-2 Family NO Synthase COX PARP	Neurological Disease Inflammation/Immunology
Rehmannioside A is a compound that can be isolated from Rehmanniae radix. Rehmannioside A is an inhibitor of CYP3A4, 2C9 and 2D6, with IC₅₀ values of 10.08, 12.62 and 16.43 μM, respectively. Rehmannioside A has anti-inflammatory, antioxidant, anti-apoptosis, anti-ferroptosis, cognitive improvement and neuroprotective activities. Rehmannioside A can be used for the research of nervous system and inflammation-related diseases .

HY-P991539

CM101	Apoptosis	Cardiovascular Disease Cancer
CM101 is an anti-pathoangiogenic polysaccharide that can be derived from group B streptococcus. CM101 can inhibit inflammatory angiogenesis and accelerate wound healing in mouse models as well as minimizing scarring after spinal cord injury. CM101 also causes rapid tumor neovascularitis, infiltration of inflammatory cells, inhibition of tumor growth and tumor apoptosis .

HY-127004

Silperisone hydrochloride RGH-5002	Sodium Channel	Others
Silperisone hydrochloride is an organosilicone compound similar to tolperisone that has centrally acting muscle relaxant properties. Silperisone (hydrochloride) is a sodium channel protein type 2 alpha channel blocker that blocks sodium and calcium channels in cells, reduces muscle cell excitability and contraction, reduces peripheral tone, and acts as a muscle relaxant and peripheral vascular dilator. Silperisone (hydrochloride) is used to study recurrent painful myoclonus due to spinal cord injury, abnormal hypertonia due to cerebrovascular disease, myotonia symptoms, pyramidal tonia syndrome, multiple sclerosis myospasm, and myelitis .

HY-P1120A

WKYMVm TFA	Formyl Peptide Receptor (FPR) PERK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
WKYMVm (TFA) is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs, and WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor .

HY-135809

A2764 dihydrochloride	Potassium Channel	Neurological Disease
A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K ⁺ channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC₅₀=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception .

HY-P1120

WKYMVm	Formyl Peptide Receptor (FPR) PERK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
WKYMVm is a selective formylpeptide receptor 2 (FPR2) agonist. WKYMVm has a powerful anti-inflammatory effect that can reduce lung injury and spinal cord injury. WKYMVm ameliorates obesity by regulating lipid metabolism and leptin signaling. WKYMVm is involved in the regulation of immune cells by activating FPRs. WKYMVm can promote the chemotactic migration of immune cells and inhibit the apoptosis of phagocytes. In addition, WKYMVm may play a favorable or unfavorable role in tumors, depending on the type of tumor .

HY-N0194

Asiatic acid 3 Publications Verification	Apoptosis Parasite	Inflammation/Immunology Cancer
Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model .

HY-125726

Sulfo galactosylceramide (3'-sulfo)Galβ-Cer(d18:1/24:1); N-Nervonoyl Sulfatide; C24:1 Sulfatide	Nuclear Factor of activated T Cells (NFAT)	Inflammation/Immunology
Sulfo galactosylceramide (N-Nervonoyl Sulfatide; C24:1 Sulfatide) is a glycolipid and the major sulfolipid species in mature myelin. Sulfo galactosylceramide interacts with C-type lectins and immunoglobulin-like receptors, with the highest affinity for LMIR5. Sulfo galactosylceramide induces MCP-1 production by basophils but not mast cells, and increases NFAT activation via LMIR5. Sulfo galactosylceramide alleviates symptoms and improves survival in a mouse model of chronic relapsing-remitting experimental autoimmune encephalomyelitis (EAE), and reduces inflammatory lesions and the number of infiltrating mononuclear cells in the lumbar spinal cord of EAE mice.

HY-P991310

Lpathomab LT3015; LT-3000	LPL Receptor	Neurological Disease Cancer
Lpathomab (LT3015; LT-3000) is a human IgG1 monoclonal antibody (mAb) targeting LPA. Lpathomab reduces the release of IL-8 and IL-6 cytokines in SKOV3 cells and blocks LPA-triggered tumor cell migration. Lpathomab reduces neovascularization in Matrigel plug and CNV models. Lpathomab inhibits brain injury in the CCI mouse model. Lpathomab can be used in the study of brain injury, ovarian cancer, diabetic neuropathy, and spinal cord injury. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-N0194R

Asiatic acid (Standard)	Reference Standards Apoptosis Parasite	Inflammation/Immunology Cancer
Asiatic acid (Standard) is the analytical standard of Asiatic acid. This product is intended for research and analytical applications. Asiatic acid, a pentacyclic triterpene found in Centella asiatica (Centella asiatica), has anticancer activity. Asiatic acid induces apoptosis in melanoma cells and has barrier protective effects on human aortic endothelial cells (HAEC). Asiatic acid also has anti-inflammatory activity and inhibits tumor necrosis factor (TNF)-α-induced endothelial barrier dysfunction. Asiatic acid also inhibits NLRP3 inflammasome activation and NF-κB pathway, effectively inhibits inflammation in rats, and has neuroprotective effects in rat spinal cord injury (SCI) model .

HY-N0837

Veratramine 1 Publications Verification NSC17821; NSC23880	PI3K Akt mTOR Autophagy Apoptosis	Neurological Disease Metabolic Disease Cancer
Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .

HY-N0837R

Veratramine (Standard) NSC17821 (Standard); NSC23880 (Standard)	Reference Standards PI3K Akt mTOR Autophagy Apoptosis	Neurological Disease Metabolic Disease Cancer
Veratramine (NSC17821; NSC23880) (Standard) is the analytical standard of Veratramine (HY-N0837). This product is intended for research and analytical applications. Veratramine (NSC17821; NSC23880) is an orally active inhibitor of the PI3K/Akt/mTOR signaling pathway and a SIGMAR1 modulator. Veratramine induces autophagic apoptosis of tumor cells, arrests the cell cycle at the G0/G1 phase, and inhibits epithelial-mesenchymal transition (EMT)-related proteins to reduce tumor migration. Veratramine reduces spinal cord and sciatic nerve pathological damage in a neuropathy model by inhibiting SIGMAR1 binding to NMDAR and phosphorylation of NMDAR Ser896. Veratramine has anti-tumor proliferation, apoptosis induction, anti-inflammatory and neuroprotective activities, and can be used in the study of cancers such as liver cancer and osteosarcoma, as well as diabetic peripheral neuropathy .

Cat. No.	Product Name	Target	Research Area